Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (Nasdaq: CLSD), a company specializing in suprachoroidal space (SCS®) therapy delivery to the back of the eye, has announced its participation in the Stifel 2024 Healthcare Conference. George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of R&D, will engage in a fireside chat on November 19, 2024, at 8:00 a.m. ET in New York.

The event will be accessible via webcast on Clearside's website under the Investors section, with the recording remaining available for three months following the presentation.

Clearside Biomedical (Nasdaq: CLSD) has appointed Tony Gibney as the new Chair of its Board of Directors, effective November 1, 2024. Gibney, who joined as an independent director in April 2024, succeeds Clay Thorp, who remains on the Board. Gibney brings over 30 years of biotechnology industry experience, most recently serving as Executive VP, Chief Business & Strategy Officer at Iveric Bio until its acquisition by Astellas Pharma in July 2023. The company highlights his strategic leadership in ophthalmics and capital markets expertise, particularly noting the recent ODYSSEY Phase 2b results with CLS-AX in wet AMD, which showed promising potential.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss results and provide a corporate update. Investors can access the webcast through Clearside's website under the Investors section, or join the call using domestic (877) 545-0523 or international (973) 528-0016 dial-in numbers with conference code 756568.

Clearside Biomedical (Nasdaq: CLSD) presented positive data from its ODYSSEY Phase 2b trial for CLS-AX in wet AMD at the 2024 AAO Annual Meeting. The trial demonstrated extended duration and stable vision, with an 84% reduction in injection frequency after the initial dose. Approximately 90% of participants did not require additional treatment up to 4 months, 81% up to 5 months, and 67% up to 6 months.

CLS-AX's target product profile aims to provide flexible dosing similar to a biologic with the potential extended duration of a tyrosine kinase inhibitor (TKI). The company believes these results support advancing CLS-AX into Phase 3 development for wet AMD. Multiple presentations highlighted the versatility of Clearside's SCS Microinjector® for delivering therapies to the back of the eye through the suprachoroidal space.

Clearside Biomedical (Nasdaq: CLSD) announced positive topline results from its ODYSSEY Phase 2b trial of CLS-AX for treating wet AMD. The trial achieved all primary and secondary outcomes, demonstrating:

1. Stable visual acuity and anatomical control over 9 months
2. Positive safety profile with no ocular or treatment-related serious adverse events
3. 67% of CLS-AX participants not requiring additional treatment up to 6 months
4. 84% reduction in treatment burden over 6 months

CLS-AX, delivered via Clearside's proprietary SCS Microinjector®, showed potential for flexible maintenance dosing between 3 to 6 months. The company plans to advance the program into Phase 3 development based on these encouraging results.

Clearside Biomedical (Nasdaq: CLSD) has announced the completion of the final participant visit in its ODYSSEY Phase 2b clinical trial of CLS-AX for wet AMD. CLS-AX is a highly potent tyrosine kinase inhibitor delivered suprachoroidally using Clearside's proprietary SCS Microinjector®. The company expects to report topline data during the week of October 7, 2024.

The ODYSSEY trial represents a significant milestone for Clearside, with the potential to offer a safer treatment option and reduced treatment burden for wet AMD patients. The company believes there is a compelling market opportunity for CLS-AX, combining the highly-potent TKI axitinib with suprachoroidal delivery. Clearside plans to present the data at events preceding the annual American Academy of Ophthalmology meeting in Chicago.

Clearside Biomedical (Nasdaq: CLSD) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Phase 2b ODYSSEY trial for CLS-AX in wet AMD on track with topline data expected in late Q3 2024.

2. Safety Review Committee recommended trial continuation with no serious adverse events observed.

3. Q2 2024 financial results: Revenue $90,000, net loss $7.6 million ($0.10 per share).

4. Cash position of $29.4 million, expected to fund operations into Q3 2025.

5. Progress in XIPERE commercialization and positive results from partner Arctic Vision's Phase 3 trial in China.

6. Advancements in suprachoroidal delivery platform and partnerships.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's management will present a corporate update available on demand from August 15, 2024, at 7:00 a.m. ET.

Additionally, Dr. Victor Chong, Chief Medical Officer, will take part in a panel discussion on the Evolving Therapeutic Landscape of AMD. Interested parties can access the live and archived webcast presentation through the Investors section of Clearside's website under Events and Presentations.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company specializing in suprachoroidal space (SCS®) therapies for eye conditions, has announced its schedule for reporting second quarter 2024 financial results. The company will release its Q2 2024 financials on Monday, August 12, 2024, after the financial markets close. Notably, Clearside has opted not to hold a Q2 2024 conference call. Instead, they recently hosted a Suprachoroidal Delivery Key Opinion Leader Webinar on July 24, 2024, with a replay available on their website. The company plans to resume quarterly earnings conference calls starting with the third quarter 2024 financial results.